KDA
- Current
- Browse
- Collections
-
For contributors
- For Authors
- Instructions for authors
- Article processing charge
- For Reviewers
- Instructions for reviewers
- How to become a reviewer
- Best reviewers
- For Readers
- Readership
- Subscription
- Permission guidelines
- About
- Editorial policy
Search
- Page Path
- HOME > Search
Original Article
- Basic and Translational Research
- Targeting PGC-1α by miRNA-374 Simultaneously Improve β-Cell Dysfunction and Suppress Hepatic Glucose Overproduction
- Ji-Won Kim, Joonyub Lee, Young-Hye You, Chan-Hee Oh, Heon-Seok Park, Eun Young Lee, Seung-Hwan Lee, Seung-Hyun Ko, Ji-Ho Park, Kun-Ho Yoon
- Received April 5, 2025 Accepted August 24, 2025 Published online November 3, 2025
- DOI: https://doi.org/10.4093/dmj.2025.0287 [Epub ahead of print]
- 1,156 View
- 52 Download
-
Abstract
PDF
Supplementary Material
PubReader 
ePub - Background
In this study, we aimed to validate the potential of miR-374 in ameliorating hyperglycemia by regulating peroxisome proliferator-activated receptor γ coactivator-1 (PGC-1α) expression in pancreatic islets and liver.
Methods
To identify miRNAs targeting PGC-1α, we performed miRNA chip analysis in rat islets under hyperglycemic and euglycemic conditions. Luciferase reporter assay was performed to identify miR binding sites in the 3’-untranslated region (3’ UTR) of PGC-1α. In db/db mice, miRNA-encapsulated adenoviruses were administered and intraperitoneal glucose tolerance test and glucose stimulated insulin secretion tests were performed. For enhanced delivery to β-cells, we developed exendin-4 (Ex-4) coated cationic lipoparticles (CCLs) encapsulating miRNAs. The therapeutic potential of Ex-4-CCL-miRNA was further evaluated in insulin-producing cells derived from induced pluripotent stem cells.
Results
By analyzing miRNA expression in primary rat islets exposed under hyperglycemic environment, we identified miR-374 as a potential target. In vitro experiments confirmed that miR-374 significantly suppressed PGC-1α expression in β-cells and hepatocytes by binding to its 3’-UTR. In vivo experiments using adenovirus-mediated miR-374 (Ad-miR-374) delivering directly to the pancreas and liver of db/db mice demonstrated improved glycemic control, enhanced insulin secretion, and downregulated hepatic gluconeogenesis-related genes (G6Pase, Pepck, PC). To enhance the clinical applicability of miR-374, we developed Ex-4-CCLs. Ex-4-CCL-miR-374 successfully alleviated hyperglycemia, restored pancreatic islet function, and decreased gluconeogenesis gene expression in db/db mice. Furthermore, Ex-4-CCL-miR-374 improved insulin secretory function in glucotoxicity-exposed human induced pluripotent stem cell-derived insulin producing cells.
Conclusion
Based on these findings, we propose that Ex-4-CCL-miR-374 as a promising therapeutic approach to reverse β-cell dysfunction and improve hepatic insulin resistance in type 2 diabetes mellitus.
Editorial
- A New Era in Islet Transplantation: Stem Cell-Derived and Gene-Edited Islet Therapies
- Joonyub Lee, Seung-Hwan Lee
- Diabetes Metab J. 2025;49(6):1201-1203. Published online November 1, 2025
- DOI: https://doi.org/10.4093/dmj.2025.0999
- 1,885 View
- 58 Download
Letter
- Association between Fatty Liver Index and Incident Diabetes according to Alcohol Consumption Status in Young Adults
- Joonyub Lee, Kyungdo Han
- Diabetes Metab J. 2025;49(6):1342-1345. Published online November 1, 2025
- DOI: https://doi.org/10.4093/dmj.2025.0992
- 1,111 View
- 18 Download
Review
- Basic and Translational Research
- Extracellular Vesicle-Mediated Network in the Pathogenesis of Obesity, Diabetes, Steatotic Liver Disease, and Cardiovascular Disease
- Joonyub Lee, Won Gun Choi, Marie Rhee, Seung-Hwan Lee
- Diabetes Metab J. 2025;49(3):348-367. Published online May 1, 2025
- DOI: https://doi.org/10.4093/dmj.2025.0184
- 6,913 View
- 223 Download
- 6 Web of Science
- 8 Crossref
-
Abstract
PDFPubReader ePub
- Extracellular vesicles (EVs) are lipid bilayer-enclosed particles carrying bioactive cargo, including nucleic acids, proteins, and lipids, facilitating intercellular and interorgan communication. In addition to traditional mediators such as hormones, metabolites, and cytokines, increasing evidence suggests that EVs are key modulators in various physiological and pathological processes, particularly influencing metabolic homeostasis and contributing to the progression of cardiometabolic diseases. This review provides an overview of the most recent insights into EV-mediated mechanisms involved in the pathogenesis of obesity, insulin resistance, diabetes mellitus, steatotic liver disease, atherosclerosis, and cardiovascular disease. EVs play a critical role in modulating insulin sensitivity, glucose homeostasis, systemic inflammation, and vascular health by transferring functional molecules to target cells. Understanding the EV-mediated network offers potential for identifying novel biomarkers and therapeutic targets, providing opportunities for EV-based interventions in cardiometabolic disease management. Although many challenges remain, this evolving field highlights the need for further research into EV biology and its translational applications in cardiovascular and metabolic health.
-
Citations
Citations to this article as recorded by
- Postbiotics in Functional Foods: Microbial Derivatives Shaping Health, Immunity and Next‐Generation Nutrition
Alice Njolke Mafe, Javad Sharifi‐Rad, Daniela Calina, Ayobami Joshua Ogunyemi, Abiola O. Tubi
Food Frontiers.2026;[Epub] CrossRef - Decoding the Endocrine Code of Skeletal Muscle: Myokines, Exerkines, and Inter-Organ Crosstalk in Metabolic Health and Disease
Young-Sool Hah, Jeongyun Hwang, Seung-Jun Lee, Seung-Jin Kwag
Cells.2026; 15(4): 318. CrossRef - Extracellular Vesicles: Biology, Intercellular Communication and Therapeutic Potential in Diabetes
Swayam Prakash Srivastava, Lydia Herrmann, Eden Ozkan, Abhiram Kunamneni, Vinamra Swaroop, Geetika Nehra, Rohit Srivastava, Pratima Tripathi, Ken Inoki, Julie E. Goodwin
Advanced Therapeutics.2026;[Epub] CrossRef - Association between dyslipidemia and elevated liver enzymes: A cross-sectional study from the PERSIAN Guilan cohort study
Milad Shahdkar, Mahdi Orang Goorabzarmakhi, Mahdi Shafizadeh, Farahnaz Joukar, Saman Maroufizadeh, Niloofar Faraji, Tahereh Zeinali, Fariborz Mansour-Ghanaei
Endocrine and Metabolic Science.2025; 19: 100272. CrossRef - Molecular Signatures of Obesity-Associated Infertility in Polycystic Ovary Syndrome: The Emerging Role of Exosomal microRNAs and Non-Coding RNAs
Charalampos Voros, Georgios Papadimas, Despoina Mavrogianni, Aristotelis-Marios Koulakmanidis, Diamantis Athanasiou, Kyriakos Bananis, Antonia Athanasiou, Aikaterini Athanasiou, Ioannis Papapanagiotou, Dimitrios Vaitsis, Charalampos Tsimpoukelis, Maria An
Genes.2025; 16(9): 1101. CrossRef - Molecular mechanisms linking adipose tissue-derived small extracellular vesicles/exosomes to the development or amelioration of obesity, insulin resistance, and diabetes-related complications
Linfeng Chen, Fatemeh Amraee, Sahar Sadegh-Nejadi, Mostafa Saberian, Seyed Arsalan Ghahari, Xiaolei Miao, Giuseppe Lisco, Reza Afrisham
European Journal of Medical Research.2025;[Epub] CrossRef - Mitochondria-Enriched Extracellular Vesicles (EVs) for Cardiac Bioenergetics Restoration: A Scoping Review of Preclinical Mechanisms and Source-Specific Strategies
Dhienda C. Shahannaz, Tadahisa Sugiura, Taizo Yoshida
International Journal of Molecular Sciences.2025; 26(22): 11052. CrossRef - A Comprehensive Insight Into the Roles of Exosomal circRNAs in Metabolic Syndrome
Azadeh Taherpour, Safieh Ebrahimi, Farshad Mirzavi
BioFactors.2025;[Epub] CrossRef
- Postbiotics in Functional Foods: Microbial Derivatives Shaping Health, Immunity and Next‐Generation Nutrition
Original Article
- Metabolic Risk/Epidemiology
- The Impact of Obesity on the Association between Parity and Risk of Type 2 Diabetes Mellitus
- Yuki Gen, Kyuho Kim, Joonyub Lee, Junyoung Jung, Sang-Hyuk Jung, Hong-Hee Won, Dokyoon Kim, Yun-Sung Jo, Yu-Bae Ahn, Seung-Hyun Ko, Jae-Seung Yun
- Diabetes Metab J. 2025;49(4):837-847. Published online February 14, 2025
- DOI: https://doi.org/10.4093/dmj.2024.0536
- 5,405 View
- 182 Download
- 1 Web of Science
- 1 Crossref
-
Abstract
PDFSupplementary MaterialPubReader ePub
- Background
Most studies focus solely on the relationship between parity and type 2 diabetes mellitus (T2DM) risk, providing limited insights into other contributing or protective factors. This study aims to explore the complex relationship between parity and T2DM risk, considering additional factors such as obesity, race, and body composition.
Methods
This prospective cohort study used data from 242,159 women aged 40 to 69 from the UK Biobank, none of whom had T2DM at baseline. Multivariable Cox proportional hazard models were applied to assess the association between parity and T2DM. Subgroup analyses were performed based on body mass index (BMI), waist circumference (WC), and race.
Results
The hazard ratio for T2DM per additional child was 1.16 (95% confidence interval, 1.13 to 1.16). Subgroup analysis revealed that Asian women and those with obesity or abdominal obesity had a higher risk of T2DM associated with multiparity. No increased risk was observed in women with normal BMI or WC. Mediation analysis showed that WC and BMI significantly mediated the parity-T2DM relationship, accounting for 49% and 38% of the effect, respectively.
Conclusion
There is a clear positive association between multiparity and T2DM risk, particularly in Asian women and those with obesity. Maintaining normal BMI and WC appears to mitigate this risk, highlighting the importance of weight management for women at higher parity levels. These findings offer crucial insights for public health interventions aimed at reducing T2DM risk among women. -
Citations
Citations to this article as recorded by- Baseline and longitudinal changes of body roundness index and incident type 2 diabetes: evidence from the UK Biobank cohort
Xuanli Zhao, Fangyuan Jing, Yanan Ren, Jing Zhu, Xinzhe Jing, Meiqun Lv, Ke Huang, Jing Guo, Jiayu Li, Xiaohui Sun, Yingying Mao, Ding Ye
BMJ Open Diabetes Research & Care.2025; 13(5): e005339. CrossRef
- Baseline and longitudinal changes of body roundness index and incident type 2 diabetes: evidence from the UK Biobank cohort
Brief Report
- Complications
- Diabetic Ketoacidosis as an Effect of Sodium-Glucose Cotransporter 2 Inhibitor: Real World Insights
- Han-Sang Baek, Chaiho Jeong, Yeoree Yang, Joonyub Lee, Jeongmin Lee, Seung-Hwan Lee, Jae Hyoung Cho, Tae-Seo Sohn, Hyun-Shik Son, Kun-Ho Yoon, Eun Young Lee
- Diabetes Metab J. 2024;48(6):1169-1175. Published online June 10, 2024
- DOI: https://doi.org/10.4093/dmj.2024.0036
- 13,493 View
- 437 Download
- 13 Web of Science
- 15 Crossref
-
Abstract
PDFPubReader ePub
- One of the notable adverse effects of sodium-glucose cotransporter 2 (SGLT2) inhibitor is diabetic ketoacidosis (DKA) often characterized by euglycemia. In this retrospective review of patients with DKA from 2015 to 2023, 21 cases of SGLT2 inhibitorassociated DKA were identified. Twelve (57.1%) exhibited euglycemic DKA (euDKA) while nine (42.9%) had hyperglycemic DKA (hyDKA). More than 90% of these cases were patients with type 2 diabetes mellitus. Despite similar age, sex, body mass index, and diabetes duration, individuals with hyDKA showed poorer glycemic control and lower C-peptide levels compared with euDKA. Renal impairment and acidosis were worse in the hyDKA group, requiring hemodialysis in two patients. Approximately one-half of hyDKA patients had concurrent hyperosmolar hyperglycemic state. Common symptoms included nausea, vomiting, general weakness, and dyspnea. Seizure was the initial manifestation of DKA in two cases. Infection and volume depletion were major contributors, while carbohydrate restriction and inadequate insulin treatment also contributed to SGLT2 inhibitor-associated DKA. Despite their beneficial effects, clinicians should be vigilant for SGLT2 inhibitor risk associated with DKA.
-
Citations
Citations to this article as recorded by- Fallbericht einer Euglykämischen Diabetischen Ketoacidose unter SGLT-2-Inhibition bei einer geriatrischen Patientin: „Sick-Day-Off Drug“
Laura Wassermann, Michael Denkinger
Zeitschrift für Gerontologie und Geriatrie.2026; 59(1): 74. CrossRef - The evolution of C-peptide's role in diabetes care
Laura Briggs, Alexander Read, Sarah Darch, Emma L. Williams, Wann Jia Loh, Julia S. Kenkre
Current Opinion in Endocrinology, Diabetes & Obesity.2026; 33(1): 16. CrossRef - Diabetic ketoacidosis is not a simple consequence of hyperglycemia, it is biochemical event driven by PDK4-mediated inhibition of PDC
Ayah Al-Qasrawi
Medical Hypotheses.2026; 208: 111898. CrossRef - Dapagliflozin/Empagliflozin/Ertugliflozin
Reactions Weekly.2025; 2042(1): 142. CrossRef - Diabetes Mellitus at an Elderly Age
Andrej Zeyfang, Jürgen Wernecke, Anke Bahrmann
Experimental and Clinical Endocrinology & Diabetes.2025; 133(04): 168. CrossRef - SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application
Jae Hyun Bae
Diabetes & Metabolism Journal.2025; 49(3): 386. CrossRef - Diabetes mellitus im Alter
Andrej Zeyfang, Jürgen Wernecke, Anke Bahrmann
Die Diabetologie.2025; 21(4): 503. CrossRef - Cardiorenal outcomes and safety of SGLT2 inhibitors in patients with diabetes secondary to disorders of the exocrine pancreas: a nationwide population-based study
Kyoung Hwa Ha, Minae Park, Yujin Lee, Dae Jung Kim, Seung Jin Han
Diabetes & Metabolism.2025; 51(5): 101668. CrossRef - SGLT2 Inhibitors: From Structure–Effect Relationship to Pharmacological Response
Teodora Mateoc, Andrei-Luca Dumitrascu, Corina Flangea, Daniela Puscasiu, Tania Vlad, Roxana Popescu, Cristina Marina, Daliborca-Cristina Vlad
International Journal of Molecular Sciences.2025; 26(14): 6937. CrossRef - Euglycaemic diabetic ketoacidosis and its risk factors in patients undergoing coronary artery bypass grafting surgery: a single-centre nested case-control study in China
Rui Hu, Congchao Lu, Yifan Liu, Mengli Yang, Hongya Xing, Kerui Dai, Jiyin Li, Hui Zheng, Xi Chen, Nai-Jun Tang
BMJ Open.2025; 15(8): e098758. CrossRef - Acute heart failure in non-cardiac surgery
Danielle M Gualandro, Josep Masip, Sigrun Halvorsen, Susanna Price, Xavier Rosselló, Ovidiu Chioncel, W Frank Peacock, Òscar Miró, Mucio Tavares Oliveira Junior, Alexandre Mebazaa, Elke Platz, Offer Amir, Hannah Schaubroeck, Johannes Grand, Alessandro Sio
European Heart Journal.2025; 46(40): 4042. CrossRef - Severe euglycemic ketoacidosis following combined therapy with GLP-1 receptor agonist and SGLT-2 inhibitor, refractory to standard treatment: a case report
Agnieszka Gandecka-Pempera, Dariusz Naskręt, Anna Adamska, Dorota Zozulińska-Ziółkiewicz
Frontiers in Endocrinology.2025;[Epub] CrossRef - Sodium-Glucose Cotransporter 2 Inhibitors-Induced Euglycemic Ketoacidosis Mimicking Myocardial Infarction in a Non-Diabetic Heart Failure Patient
KilYoon Pack, Kyung Eun Ha, Taeil Yang, Wook-Jin Chung
International Journal of Heart Failure.2025; 7(4): 257. CrossRef - Diabetes mellitus im Alter
Andrej Zeyfang, Jürgen Wernecke, Anke Bahrmann
Diabetologie und Stoffwechsel.2025; 20(S 02): S234. CrossRef - Diabetes mellitus im Alter
Andrej Zeyfang, Jürgen Wernecke, Anke Bahrmann
Diabetologie und Stoffwechsel.2024; 19(S 02): S226. CrossRef
- Fallbericht einer Euglykämischen Diabetischen Ketoacidose unter SGLT-2-Inhibition bei einer geriatrischen Patientin: „Sick-Day-Off Drug“
Original Article
- Drug/Regimen
- Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial
- Ji-Yeon Park, Joonyub Lee, Yoon-Hee Choi, Kyung Wan Min, Kyung Ah Han, Kyu Jeung Ahn, Soo Lim, Young-Hyun Kim, Chul Woo Ahn, Kyung Mook Choi, Kun-Ho Yoon, the Practical Evidence of Antidiabetic Combination Therapy in Korea (PEAK) study investigators
- Diabetes Metab J. 2024;48(5):915-928. Published online April 23, 2024
- DOI: https://doi.org/10.4093/dmj.2023.0259
- 10,666 View
- 394 Download
- 3 Web of Science
- 5 Crossref
-
Abstract
PDFSupplementary MaterialPubReader ePub
- Background
Guidelines for switching to triple combination therapy directly after monotherapy failure are limited. This study investigated the efficacy, long-term sustainability, and safety of either mono or dual add-on therapy using alogliptin and pioglitazone for patients with type 2 diabetes mellitus (T2DM) who did not achieve their target glycemic range with metformin monotherapy.
Methods
The Practical Evidence of Antidiabetic Combination Therapy in Korea (PEAK) was a multicenter, placebo-controlled, double-blind, randomized trial. A total of 214 participants were randomized to receive alogliptin+pioglitazone (Alo+Pio group, n=70), alogliptin (Alo group, n=75), or pioglitazone (Pio group, n=69). The primary outcome was the difference in glycosylated hemoglobin (HbA1c) levels between the three groups at baseline to 24 weeks. For durability, the achievement of HbA1c levels <7% and <6.5% was compared in each group. The number of adverse events was investigated for safety.
Results
After 24 weeks of treatment, the change of HbA1c in the Alo+Pio, Alo, and Pio groups were –1.38%±0.08%, –1.03%±0.08%, and –0.84%±0.08%, respectively. The Alo+Pio group had significantly lower HbA1c levels than the other groups (P=0.0063, P<0.0001) and had a higher proportion of patients with target HbA1c achievement. In addition, insulin sensitivity and β-cell function, lipid profiles, and other metabolic indicators were also improved. There were no significant safety issues in patients treated with triple combination therapy.
Conclusion
Early combination triple therapy showed better efficacy and durability than the single add-on (dual) therapy. Therefore, combination therapy with metformin, alogliptin, and pioglitazone is a valuable early treatment option for T2DM poorly controlled with metformin monotherapy. -
Citations
Citations to this article as recorded by- Fixed-dose combinations of hypoglycemic drugs: potential of alogliptin/pioglitazone in type 2 diabetes mellitus: a review
Olga I. Butranova, Sergey K. Zyryanov, Anna R. Melnikova, Anastasia E. Matsepuro
Terapevticheskii arkhiv.2025; 97(8): 735. CrossRef - Triple oral therapy with metformin, DPP‐4 inhibitor, and SGLT2 inhibitor for adults with type 2 diabetes: Consensus recommendations of a Chinese expert panel (version 2025)
Miao Yu, Tong Wang, Chun Xu, Yan Bi, Ling Gao, Guang Wang, Guangda Xiang, Yaoming Xue, Tao Yang, Deying Kang, Zhiguang Zhou, Lixin Guo, Xinhua Xiao
Diabetes, Obesity and Metabolism.2025; 27(S9): 3. CrossRef - Thiazolidinediones for people with chronic kidney disease and diabetes
Patrizia Natale, Suetonia C Green, David J Tunnicliffe, Giovanni Pellegrino, Tadashi Toyama, Pantelis Sarafidis, Giovanni FM Strippoli
Cochrane Database of Systematic Reviews.2025;[Epub] CrossRef - Targeting adipose remodeling: Synergistic mechanisms of drugs and adipose-derived stem cells in obese type 2 diabetes mellitus
Cheng Luo, Xian-Mei Yu, Liang-Yan Hua, Mei-Qi Zeng, Hui Xu, Cheng-Zheng Duan, Shi-Yu Xu, Da Sun, Li-Ya Ye, Dong-Juan He
World Journal of Stem Cells.2025;[Epub] CrossRef - Nuclear receptors as therapeutic targets in metabolic and cardiovascular disorders
Feifei Li, Qiujing Chen, Yang Dai, Lin Lu
iScience.2025; 28(12): 114042. CrossRef
- Fixed-dose combinations of hypoglycemic drugs: potential of alogliptin/pioglitazone in type 2 diabetes mellitus: a review
Sulwon Lecture 2022
- Others
- Opening the Precision Diabetes Care through Digital Healthcare
- Joonyub Lee, Jin Yu, Kun-Ho Yoon
- Diabetes Metab J. 2023;47(3):307-314. Published online March 29, 2023
- DOI: https://doi.org/10.4093/dmj.2022.0386
- 17,460 View
- 387 Download
- 7 Web of Science
- 7 Crossref
-
Abstract
PDFPubReader ePub
- The national healthcare systems of every country in the world cannot sustain the rise in healthcare expenditure caused by chronic diseases and their complications. To sustain the national healthcare system, a novel system should be developed to improve the quality of care and minimize healthcare costs. For 20 years, our team developed patient-communicating digital healthcare platforms and proved their efficacy. National scale randomized control trials are underway to systematically measure the efficacy and economic benefits of this digital health care system. Precision medicine aims to maximize effectiveness of disease management by considering individual variability. Digital health technologies enable precision medicine at a reasonable cost that was not available before. The government launched the “National Integrated Bio-big Data Project” which will collect diverse health data from the participants. Individuals will share their health information to physicians or researchers at their will by gateway named “My-Healthway.’ Taken together, now we stand in front of the evolution of medical care, so-called “Precision medicine.” led by various kinds of technologies and a huge amount of health information exchange. We should lead these new trends as pioneers, not as followers, to establish and implement the best care for our patients that can help them to withstand their devastating diseases.
-
Citations
Citations to this article as recorded by- Federated multimodal AI for precision-equitable diabetes care
Bing Bai, Xilin Liu, Hong Li
Frontiers in Digital Health.2026;[Epub] CrossRef - Social determinants of health and type 2 diabetes in Asia
Kyunghun Sung, Seung‐Hwan Lee
Journal of Diabetes Investigation.2025; 16(6): 971. CrossRef - Digital health: current applications, challenges, and future directions for enhancing healthcare quality and safety
Saidi Hu, Danyang Song, Siran Wan, Shunhong Zhang, Chenchen Luo, Nian Li, Guangyue Liu, Jailson da Graça Espírito Santo Vasconcelos, Leonilde Lavres Ceita de Carvalho, Eveline Neobísi, Monazeri Lima Bragança da Costa, José Etchu Takounjou, Karem Maimite D
Frontiers in Public Health.2025;[Epub] CrossRef - A New Era in Islet Transplantation: Stem Cell-Derived and Gene-Edited Islet Therapies
Joonyub Lee, Seung-Hwan Lee
Diabetes & Metabolism Journal.2025; 49(6): 1201. CrossRef - Bridging the digital divide: student-led literacy initiatives in diabetes management
Pedro Almeida Moyano, Mohammed Raddaoui, Andrea de Barros Coscelli Ferraz, Gustavo José Martiniano Porfírio, Luciana Aparecida Campos, Ovidiu Constantin Baltatu
Frontiers in Clinical Diabetes and Healthcare.2025;[Epub] CrossRef - Technological Innovations Transforming Diabetes Care in Practice
Shinae Kang
The Journal of Korean Diabetes.2024; 25(2): 57. CrossRef - Islet transplantation in Korea
Joonyub Lee, Kun‐Ho Yoon
Journal of Diabetes Investigation.2024; 15(9): 1165. CrossRef
- Federated multimodal AI for precision-equitable diabetes care
Corrigendum
- Early Glycosylated Hemoglobin Target Achievement Predicts Clinical Outcomes in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
- Joonyub Lee, Jae Hyoung Cho
- Diabetes Metab J. 2021;45(4):621-621. Published online July 30, 2021
- DOI: https://doi.org/10.4093/dmj.2021.0119
- Corrects: Diabetes Metab J 2021;45(3):337
- 4,914 View
- 82 Download
- 1 Crossref
Editorial
- Early Glycosylated Hemoglobin Target Achievement Predicts Clinical Outcomes in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
- Joonyub Lee, Jae Hyoung Cho
- Diabetes Metab J. 2021;45(3):337-338. Published online May 25, 2021
- DOI: https://doi.org/10.4093/dmj.2021.0078
- Correction in: Diabetes Metab J 2021;45(4):621
- 6,899 View
- 237 Download
- 9 Web of Science
- 7 Crossref
-
PDFPubReader ePub
-
Citations
Citations to this article as recorded by- Effects of nurse-led telephone interventions on HbA1c levels in patients with type 2 diabetes: a Meta-analysis-based evaluation of follow-up protocols
Yinhai Chen, Tong Zhou, Lin Su, Youpeng Guo, Xiong Ke
BMC Nursing.2025;[Epub] CrossRef - Predictive value of stress hyperglycaemia ratio for 28-day all-cause mortality in elderly patients with hip fracture: a retrospective single-centre study in Beijing Jishuitan Hospital, Capital Medical University, Beijing, China
Xue Zhan, Hao Wang, Ying Bai
BMJ Open.2025; 15(11): e105498. CrossRef - Multi‐Omics Decoding of Dendrobium huoshanense's Dual‐Target Mechanism: Modulating Purine and Ether Lipid Metabolism for Type 2 Diabetes Therapy
Jun Dai, Zhibo Wang, Xian Wang, Sifan Guo, Yan Wang, Ying Cai, Dandan Xie, Yujuan Wang, Aihua Zhang, Shi Qiu, Shaojiang Zheng
eFood.2025;[Epub] CrossRef - Multidisciplinary continuing care practice of specialist nurses in daytime robotic surgery for patients with adrenal tumors complicated by diabetes mellitus
Ruishuang Pang, Yanghao Tai, Xue Yao, Kang Wang, Jiwen Shang, Qi Gao
Journal of Robotic Surgery.2025;[Epub] CrossRef - Evaluation of Left Ventricular Function in Diabetes Patients with Microvascular Disease by Three-Dimensional Speckle Tracking Imaging
青 周
Advances in Clinical Medicine.2023; 13(12): 18908. CrossRef - Association of long-term visit-to-visit variability of HbA1c and fasting glycemia with hypoglycemia in type 2 diabetes mellitus
Chen Long, Yaling Tang, Jiangsheng Huang, Suo Liu, Zhenhua Xing
Frontiers in Endocrinology.2022;[Epub] CrossRef - Time to Reach Target Glycosylated Hemoglobin Is Associated with Long-Term Durable Glycemic Control and Risk of Diabetic Complications in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A 6-Year Observational Study (Diabetes Metab J 2021;45:368-78)
Kyoung Jin Kim, Jimi Choi, Jae Hyun Bae, Kyeong Jin Kim, Hye Jin Yoo, Ji A Seo, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Sin Gon Kim, Nam Hoon Kim
Diabetes & Metabolism Journal.2021; 45(4): 617. CrossRef
- Effects of nurse-led telephone interventions on HbA1c levels in patients with type 2 diabetes: a Meta-analysis-based evaluation of follow-up protocols
Original Article
- Pathophysiology
-
- Essential Role of Protein Arginine Methyltransferase 1 in Pancreas Development by Regulating Protein Stability of Neurogenin 3
- Kanghoon Lee, Hyunki Kim, Joonyub Lee, Chang-Myung Oh, Heein Song, Hyeongseok Kim, Seung-Hoi Koo, Junguee Lee, Ajin Lim, Hail Kim
- Diabetes Metab J. 2019;43(5):649-658. Published online April 8, 2019
- DOI: https://doi.org/10.4093/dmj.2018.0232
- 9,327 View
- 84 Download
- 10 Web of Science
- 10 Crossref
-
Abstract
PDFPubReader ePub
Background Protein arginine methyltransferase 1 (PRMT1) is a major enzyme responsible for the formation of methylarginine in mammalian cells. Recent studies have revealed that PRMT1 plays important roles in the development of various tissues. However, its role in pancreas development has not yet been elucidated.
Methods Pancreatic progenitor cell-specific
Prmt1 knock-out (Prmt1 PKO) mice were generated and characterized for their metabolic and histological phenotypes and their levels ofNeurog3 gene expression and neurogenin 3 (NGN3) protein expression. Protein degradation assays were performed in mPAC cells.Results Prmt1 PKO mice showed growth retardation and a severely diabetic phenotype. The pancreatic size and β-cell mass were significantly reduced inPrmt1 PKO mice. Proliferation of progenitor cells during the secondary transition was decreased and endocrine cell differentiation was impaired. These defects in pancreas development could be attributed to the sustained expression of NGN3 in progenitor cells. Protein degradation assays in mPAC cells revealed that PRMT1 was required for the rapid degradation of NGN3.Conclusion PRMT1 critically contributes to pancreas development by destabilizing the NGN3 protein.
-
Citations
Citations to this article as recorded by- Protein Arginine Methyltransferase 1: A Multi-Purpose Player in the Development of Cancer and Metabolic Disease
Daphne de Korte, Menno Hoekstra
Biomolecules.2025; 15(2): 185. CrossRef - Protein arginine methyltransferase 1 stimulates basal cell proliferation and migration to maintain corneal epithelial homeostasis
Jia Yang, Mingzheng Hu, Mulin Yang, Hua Ni, Jun Zhou, Dengwen Li, Jie Ran, Min Liu
Cell Death Discovery.2025;[Epub] CrossRef - Protein arginine methyltransferase 1 regulates mouse enteroendocrine cell development and homeostasis
Zhaoyi Peng, Lingyu Bao, James Iben, Shouhong Wang, Bingyin Shi, Yun-Bo Shi
Cell & Bioscience.2024;[Epub] CrossRef - Role of protein arginine methyltransferase 1 in obesity‐related metabolic disorders: Research progress and implications
Xiaolei Xuan, Yongjiao Zhang, Yufan Song, Bingyang Zhang, Junjun Liu, Dong Liu, Sumei Lu
Diabetes, Obesity and Metabolism.2024; 26(9): 3491. CrossRef - Protein Arginine Methyltransferases: Emerging Targets in Cardiovascular and Metabolic Disease
Yan Zhang, Shibo Wei, Eun-Ju Jin, Yunju Jo, Chang-Myung Oh, Gyu-Un Bae, Jong-Sun Kang, Dongryeol Ryu
Diabetes & Metabolism Journal.2024; 48(4): 487. CrossRef - Arginine 65 methylation of Neurogenin 3 by PRMT1 is required for pancreatic endocrine development of hESCs
Gahyang Cho, Kwangbeom Hyun, Jieun Choi, Eunji Shin, Bumsoo Kim, Hail Kim, Jaehoon Kim, Yong-Mahn Han
Experimental & Molecular Medicine.2023; 55(7): 1506. CrossRef - Protein arginine methyltransferase 1 in the generation of immune megakaryocytes: A perspective review
Xinyang Zhao, Zechen Chong, Yabing Chen, X. Long Zheng, Qian-Fei Wang, Yueying Li
Journal of Biological Chemistry.2022; 298(11): 102517. CrossRef - Arginine 65 Methylation of Neurogenin 3 by PRMT1 Is Required for Pancreatic Endocrine Development of hESCs
Gahyang Cho, Kwangbeom Hyun, Jieun Choi, Eun Ji Shin, Bumsoo Kim, Hail Kim, Jaehoon Kim, Yong-Mahn Han
SSRN Electronic Journal .2022;[Epub] CrossRef - Protein Arginine Methyltransferase 1 Is Essential for the Meiosis of Male Germ Cells
Sahar Waseem, Sudeep Kumar, Kanghoon Lee, Byoung-Ha Yoon, Mirang Kim, Hail Kim, Keesook Lee
International Journal of Molecular Sciences.2021; 22(15): 7951. CrossRef - Proteome-Wide Alterations of Asymmetric Arginine Dimethylation Associated With Pancreatic Ductal Adenocarcinoma Pathogenesis
Meijin Wei, Chaochao Tan, Zhouqin Tang, Yingying Lian, Ying Huang, Yi Chen, Congwei Chen, Wen Zhou, Tao Cai, Jiliang Hu
Frontiers in Cell and Developmental Biology.2020;[Epub] CrossRef
- Protein Arginine Methyltransferase 1: A Multi-Purpose Player in the Development of Cancer and Metabolic Disease
First
Prev
